Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal
Nuwellis, a medical technology company focused on improving patient outcomes through advanced fluid management, announced it has signed a non-binding letter of intent (LOI) to acquire Rendiatech, Ltd., an Israeli-based medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition is expected to support Nuwellis’ strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies that provide clinicians with earlier insight into fluid status and kidney function.
As part of the proposed transaction, Nuwellis would add to its product portfolio Rendiatech’s Clarity RMS, an FDA-cleared critical care monitoring system that continuously measures urine flow and automatically sends data and alerts of fluctuations to medical staff in real-time. Rendiatech’s next-generation system, Clarity Prime, is currently in development to advance urine monitoring capabilities, offering clinicians critical insights into renal and cardiovascular health.
“We have embarked on a transformational growth strategy to accelerate our path to cash flow positive. We believe this LOI marks an important synergistic step that has the potential to be a leap forward in realizing our strategic vision. Rendiatech’s technologies align with our deliberate focus on comprehensive fluid management, complementing our current offering and reaching the same critical care call points we already serve, all of which we believe will unlock value for all stakeholders,” said John Erb, CEO of Nuwellis.
Read More: SalesTechStar Interview with Jagan Reddy, Founder and CEO of RightRev
“We’re excited by the possibility of partnering with Nuwellis to expand access to our next-generation technology,” said Avi Kleiman, CEO of Rendiatech. “Their commercial reach and commitment to advancing fluid management make them an ideal strategic fit as we look to scale clinical adoption.”
Real-time urine output monitoring is increasingly recognized as a critical indicator for acute kidney injury (AKI), fluid responsiveness, and treatment efficacy—areas where actionable insights may significantly improve outcomes, particularly in complex ICU patients. AKI is seen in 10% to 20% of people admitted to hospital as emergencies, with an inpatient mortality over 20%1. The overall incidence of AKI in the ICU is higher at 20% to 50% and it is associated with mortality over 50%1. The Company believes that this technology has the potential to change the current pathway and may lead to improved outcomes through earlier detection of AKI and dehydration.
A 45-day due diligence period has commenced. Should both parties agree to proceed, the transaction is anticipated to close in the fourth quarter of 2025, pending final Board approval and closing conditions.
“This is a potential milestone in our continued evolution,” Erb added. “We believe that adding real-time monitoring technologies to our portfolio could strengthen our ability to deliver precise, proactive fluid management across a range of critical conditions.”
Read More: The Invisible Deal Magnet: How Salestech Activates Predictive Engagement from Unseen Buyer Signals
